Navigation Links
Striking a Gold Mine: H5N1 Vaccine may Serve as an Antidote for Mutants and Variants

As a breather and news that spells heaven for millions of avian influenza patients there is a research by scientists at St. Jude Children’s Research Hospital //. According to them they have developed in the lab a vaccine that is potent against one antigenic variant of the avian influenza virus H5N1. The scientific discovery is that this vaccine also has the ability to protect humans against future variants/mutants of the virus.

The great thing about such vaccines is that these can be used as stockpiles of medicine and used as and when required. This would save time and many lives unless new vaccines can be found against those variants.

A prepublication report on the study appears in the online issue of Journal of Infectious Diseases (JID).

The researchers showed that the vaccine completely protected ferrets from a lethal nasal infection against not only the original virus the vaccine was made to thwart, but also against a newer variant that has already proved fatal to humans. The ferrets experienced a more significant reduction of virus multiplication than otherwise would have occurred, the researchers reported. Moreover, the infections failed to spread out of the upper respiratory tract to the lungs or brain.

“These findings are especially significant because ferrets are known to be an excellent and accurate model of influenza infection and immune response in humans,” said Elena Govorkova, Ph.D., a staff scientist in the Department of Infectious Diseases at St. Jude. “Restricting the infection to the upper respiratory tract is important since in humans the virus has been isolated from specimens taken from the cerebrospinal fluid, feces, throat and blood serum. Therefore, limiting the spread of virus in an infected human is crucial to saving that person’s life.” Govorkova is the lead author of the JID paper and led the research team conducting the study.

The team also showed that the optimal strategy for vaccinatio
'"/>




Page: 1 2

Related medicine news :

1. Signature Campaign: Striking doctors take to the streets
2. Striking Doctors Urged By AP High Court To End Strike
3. Striking Doctors Form Human Chain, Block Traffic
4. Striking Students Asked to Vacate Hostels
5. President Kalam Meets Striking Medicos However Stir to Continue
6. Supreme Court Verdict Gives Hope to Striking Medicos
7. President Kalam Meets Striking Medicos However Stir to Continue
8. Supreme Court Verdict Gives Hope to Striking Medicos
9. Ramadoss Examines Patients At AIIMS, Warns Striking Doctors
10. Supreme Court Orders Striking Medicos To Call Off Agitation Immediate
11. No Punitive Action Against Striking Medicos if Strike Called Off
Post Your Comments:
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8